JETCRAFT
15.6.2020 15:02:13 CEST | Business Wire | Press release
Jetcraft , the largest international buyer and seller of business aircraft, is teaming up with the leading independent provider of maintenance support programs, Jet Support Services, Inc. (JSSI), to offer customers worldwide a unique, post-purchase unscheduled maintenance program for virtually all business jet makes and models.
The six-month post-purchase program will cover engines, airframe and APU after closing on all in-service aircraft acquired through Jetcraft.
Chad Anderson, president at Jetcraft, says: “What we are offering is peace of mind for aircraft buyers. Owners can feel confident in their new aircraft because, with this program, we are standing by the quality of the products in our inventory. Sellers who list with Jetcraft will also have an additional feature, which cannot be offered by any other dealer, to use in the marketing of their aircraft.
“In conjunction with a leading provider of support programs worldwide, this is one of the many ways we are upgrading our service offering during the COVID-19 pandemic and beyond.”
The program is solely for Jetcraft customers, who benefit from the company's unique position situated between a traditional broker and original equipment manufacturer (OEM).
Anderson continues: “We have a wide range of models available within our inventory, suitable for someone seeking their first aircraft or moving to a longer-range jet, and we are still able to complete transactions during this time. For those with the ability to purchase an aircraft or upgrade, there is plenty to take advantage of right now.”
Francisco Zozaya, SVP business development & strategy at JSSI, says: “With JSSI’s global reach, we’re confident we’ll be able to support Jetcraft customers wherever they are based. We pride ourselves on our international expertise, with technical advisors in every market who speak the local language, know the region’s culture and understand clients’ needs. Our service record is our true differentiator in the industry, and we believe aircraft owners new to JSSI will be impressed by the level of support we offer.”
Jetcraft customers who purchase an aircraft with JSSI’s six-month post-purchase coverage can subsequently enroll in full coverage JSSI programs.
All enrollments are subject to JSSI and Jetcraft approval. Some exclusions apply. Avionics coverage cannot be selected without airframe coverage; APU coverage cannot be selected without airframe or engine coverage.
ENDS
About Jetcraft
Jetcraft is the leader in international aircraft sales, marketing and ownership strategies, managing and maintaining over 20 regional offices globally. The company’s unparalleled success over more than 55 years in business aviation has earned it a world-class reputation, along with an exceptional customer base, a wide network of connections and one of the largest inventories within the industry.
For more information, please visit www.jetcraft.com
About Jet Support Services, Inc.
For more than 30 years, Jet Support Services, Inc. (JSSI), has been the leading independent provider of maintenance support and financial services to the business aviation industry. The company provides hourly cost maintenance programs to manage the often unpredictable costs of operating and maintaining virtually all makes and models of aircraft, engines and auxiliary power units (APUs). JSSI is responsible for maintaining in excess of 2,000 business jets, regional jets and helicopters across the globe and serves customers through an infrastructure of certified technical advisors.
JSSI’s portfolio of companies leverage its technical knowledge, experience, buying power and data to provide support at every stage of the aircraft life cycle; from aircraft acquisition to aircraft teardown and part out. In 2020, JSSI was recognized as a US Best Managed Company.
For more information, visit jetsupport.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200615005059/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom